Search research articles
Contact Us
Filters
Showing results (231-240 of 278) with videos related to
Page
of 28
Sort By:
The New England Journal of Medicine
|
October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancer
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
JAMA Oncology
|
June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
Miguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Karama Asleh, Ana Lluch, Angela Goytain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
Veronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Frontiers in Oncology
|
May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Tomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
JAMA Oncology
|
September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial
Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2018
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
Isabel Echavarria, Sara López-Tarruella, Antoni Picornell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Daniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 278) with videos related to
Sort By:
Page
of 28
The New England Journal of Medicine
|
October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancer
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
JAMA Oncology
|
June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
Miguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Karama Asleh, Ana Lluch, Angela Goytain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
Veronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Frontiers in Oncology
|
May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Tomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
JAMA Oncology
|
September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial
Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2018
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
Isabel Echavarria, Sara López-Tarruella, Antoni Picornell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Daniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
Page
of 28